Global #1 RV rental operator trading at $2.02 vs $6.55 fair value (224% upside). Tourism recovery from 85% to 100%+ of 2019 levels drives fleet utilisation and margin expansion, though execution risks remain.
View noteSELL rating with fair value $0.40 vs current $0.62. EBITDA margins compressing from 60.9% to 44% as competitive threats emerge.
View noteBUY rating with $2.19 fair value vs $1.94 current price. 24.8% ROIC, debt-free balance sheet, 21-year safety record. Infrastructure supercycle exposure.
View noteSigma Healthcare trades at $3.03 versus $1.33 fair value (56% downside). Strong integration progress but extreme overvaluation at 32.5x EV/EBITDA.
View noteRMA Global trades at $3.50 vs $0.170 fair value assessment. Platform transformation achieving positive cash flow with 35% revenue growth potential through US expansion. Price verification critical.
View noteClinical-stage RNA therapeutics with validated platform technology trading at $1.26 versus $14.41 fair value, offering 1,044% upside potential for growth investors.
View noteAustralia's #4 health insurer trades 15% above A$6.48 fair value. Strong 15.1% ROIC offset by transformation execution risks. Quality franchise, challenging outlook.
View noteHOLD rating with $4.73 fair value vs $4.25 current price. Regional bank executing Auswide merger targeting $20-25m synergies, 11.3% upside potential.
View noteHigh-grade copper miner trading at $18.55 vs $12.73 fair value. EBITDA margins 49.4%, ROIC 16.8%. Harmony acquisition pending at 46% premium.
View noteStrong sell recommendation with 47% downside to $21.77 fair value. Exceptional margins unsustainable as competition intensifies.
View noteJumbo Interactive trades at $11.39 vs $10.37 fair value. Strong 47% margins offset by 69% TLC dependency and 2030 renewal risk.
View noteClinical-stage biotechnology with 79% Phase 1b response rate trading at $0.275 versus $4.12 fair value, offering 1,371% upside through allogeneic CAR T platform advantages.
View note